The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study

被引:31
作者
Hayhurst, KP [1 ]
Brown, P
Lewis, SW
机构
[1] Univ Manchester, Wythenshawe Hosp, Sch Psychiat & Behav Sci, Manchester M23 9LT, Lancs, England
[2] Manchester Mental Hlth Partnership, Dept Pharm, Manchester, Lancs, England
关键词
antipsychotic; clozapine; cost-effectiveness; schizophrenia;
D O I
10.1177/026988110201600208
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A retrospective cohort study,with a-mirror-image design; was used to measure inpatient service utilization in 63 consecutive patients started on clozapine from a geographical catchment area compared to a control group matched for previous inpatient service use. An intent-to-treat analysis, including those patients (n = 28) who discontinued clozapine during the study period, showed a significant reduction in number of admissions and total time spent in hospital in the 2 years following clozapine initiation compared to the previous 2 years and to the follow-up period in the control group. This translated into a reduction of 7300 in hospitalization costs per patient started on clozapine, over-the 2-year period. In those patients who continued clozapine treatment for the whole of the 2-year period, there was a two-thirds reduction in number of admissions and total time spent in hospital compared to no change in the clozapine discontinuers. These findings suggest that clozapine is a clinically and cost-effective intervention for severe schizophrenia in routine clinical settings.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 50 条
[1]   Cost-effectiveness of clozapine - A UK clinic-based study [J].
Aitchison, KJ ;
Kerwin, RW .
BRITISH JOURNAL OF PSYCHIATRY, 1997, 171 :125-130
[2]   THE TAPS PROJECT .13. CLINICAL AND SOCIAL OUTCOMES OF LONG-STAY PSYCHIATRIC-PATIENTS AFTER ONE YEAR IN THE COMMUNITY [J].
ANDERSON, J ;
DAYSON, D ;
WILLS, W ;
GOOCH, C ;
MARGOLIUS, O ;
ODRISCOLL, C ;
LEFF, J .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 162 :45-56
[3]   Patients' and relatives' assessment of clozapine treatment [J].
Angermeyer, MC ;
Löffler, W ;
Müller, P ;
Schulze, B ;
Priebe, S .
PSYCHOLOGICAL MEDICINE, 2001, 31 (03) :509-517
[4]  
[Anonymous], ANN CLIN PSYCHIAT
[5]   Antipsychotics - The future of schizophrenia treatment [J].
Beaumont, G .
CURRENT MEDICAL RESEARCH AND OPINION, 2000, 16 (01) :37-42
[6]   Health status and health care costs for publicly funded patients with schizophrenia started on clozapine [J].
Blieden, N ;
Flinders, S ;
Hawkins, K ;
Reid, M ;
Alphs, LD ;
Arfken, CL .
PSYCHIATRIC SERVICES, 1998, 49 (12) :1590-1593
[7]  
BREIER A, 1993, HOSP COMMUNITY PSYCH, V44, P1145
[8]  
BREIER A, 1994, AM J PSYCHIAT, V151, P20
[9]  
CARPENTER WT, 1995, AM J PSYCHIAT, V152, P827
[10]   Evaluation of treatment-resistant schizophrenia [J].
Conley, RR ;
Buchanan, RW .
SCHIZOPHRENIA BULLETIN, 1997, 23 (04) :663-674